ARID2 (AT-rich interaction domain 2) is a crucial component of the SWI/SNF chromatin remodeling complex, playing a pivotal role in regulating gene expression by modulating the accessibility of chromatin. This protein is involved in a myriad of cellular processes including differentiation, proliferation, DNA repair, and development. As part of the SWI/SNF complex, ARID2 facilitates the binding of the complex to chromatin, thereby enabling the ATP-dependent remodeling of chromatin structure. This activity is essential for the transcriptional regulation of genes involved in cell cycle control and tumor suppression, underscoring ARID2's role in maintaining genomic stability and disrupting oncogenic transformation. The function of ARID2 within the SWI/SNF complex highlights its importance in the dynamic regulation of chromatin architecture, allowing for the precise control of gene expression in response to cellular signals and environmental cues.
The activation of ARID2 and its incorporation into the SWI/SNF complex is governed by a series of complex interactions and post-translational modifications that ensure its proper function and localization. The assembly of the SWI/SNF complex, including ARID2, is a tightly regulated process that is influenced by various signaling pathways, indicating that ARID2's activity is modulated in response to specific cellular needs and conditions. Phosphorylation, acetylation, and ubiquitination are among the modifications that can affect ARID2's function, altering its interaction with DNA and other components of the SWI/SNF complex. These modifications can serve as signals for the recruitment or release of ARID2 from the chromatin, thereby regulating the activity of the complex and its ability to remodel chromatin. The intricate regulation of ARID2's activation and its role in chromatin remodeling underscore the sophisticated mechanisms cells employ to control gene expression and respond to developmental and environmental changes. Understanding the mechanisms underlying ARID2 activation provides insights into the fundamental processes of chromatin dynamics and gene regulation, revealing the complexity of cellular functioning and the critical role of chromatin remodeling in health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor indirectly influencing ARID2. 5-Azacytidine modulates DNA methylation patterns, leading to altered chromatin structure and influencing ARID2 function in chromatin remodeling. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor indirectly activating ARID2. SB431542 suppresses TGF-β signaling, leading to the upregulation of ARID2 expression and subsequent modulation of chromatin remodeling. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
GLUT1 inhibitor indirectly activating ARID2. 2-Deoxyglucose modulates glucose metabolism, leading to enhanced expression of ARID2 and subsequent modulation of chromatin remodeling. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid receptor agonist indirectly activating ARID2. ATRA influences retinoic acid signaling, leading to enhanced expression of ARID2 and subsequent modulation of chromatin remodeling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor indirectly activating ARID2. PD98059 inhibits the MEK/ERK pathway, leading to enhanced expression of ARID2 and subsequent modulation of chromatin remodeling. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
BET bromodomain inhibitor indirectly activating ARID2. I-BET151 modulates the acetylation status of chromatin, leading to enhanced expression of ARID2 and subsequent modulation of chromatin remodeling. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
JMJD3 inhibitor indirectly activating ARID2. GSK-J4 inhibits JMJD3, leading to increased H3K27me3 levels and enhanced expression of ARID2, subsequently modulating chromatin remodeling. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
DOT1L inhibitor indirectly activating ARID2. SP2509 modulates H3K79 methylation, leading to enhanced expression of ARID2 and subsequent modulation of chromatin remodeling. | ||||||